Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes

CARLSBAD, Calif., Jan. 4, 2017 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced positive data from a Phase 2 study of IONIS-GCGRRx in 79 patients with type 2 diabetes. In this study, patients with type 2 diabetes uncontrolled on stable, maximal metformin… http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-reports-positive-data-from-phase-2-study-of-ionis-gcgr-rx-in-patients-with-type-2-diabetes-300385182.html